TGA published a new checklist requiring prescribing psychiatrists to document adherence to clinical protocols and safety monitoring, including adverse event reporting for these unapproved substances.
This checklist formalizes safety reporting expectations for MDMA and psilocybine prescriptions, ensuring consistent monitoring and ICSR submission to the TGA.
Review and implement the TGA checklist for all psychiatrist prescribers of MDMA/psilocybine; update ICSR workflows to capture adverse events as per checklist requirements.
Regulatory Intelligence Lead
monthly
New compliance checklist for psychiatrists covering clinical protocol adherence and safety monitoring for MDMA and psilocybine.
Prescribing psychiatrists must use this checklist to ensure all safety monitoring and reporting obligations for these unapproved substances are met, including adverse event reporting to the TGA.
Review and implement the TGA checklist for all psychiatrist prescribers of MDMA/psilocybine; update ICSR workflows to capture adverse events as per checklist requirements.
The TGA issued a compliance checklist for psychiatrists authorized to prescribe MDMA and psilocybine, outlining safety monitoring and adverse event reporting obligations.
What changed: TGA published a new checklist requiring prescribing psychiatrists to document adherence to clinical protocols and safety monitoring, including adverse event reporting for these unapproved substances.
Why it matters: This checklist formalizes safety reporting expectations for MDMA and psilocybine prescriptions, ensuring consistent monitoring and ICSR submission to the TGA.
Practical implication: Review and implement the TGA checklist for all psychiatrist prescribers of MDMA/psilocybine; update ICSR workflows to capture adverse events as per checklist requirements.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
